Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jacqueline E Lynch"'
Autor:
Deborah M. Eaton, Remus M. Berretta, Jacqueline E. Lynch, Joshua G. Travers, Ryan D. Pfeiffer, Michelle L. Hulke, Huaqing Zhao, Alexander R. H. Hobby, Giana Schena, Jaslyn P. Johnson, Markus Wallner, Edward Lau, Maggie P. Y. Lam, Kathleen C. Woulfe, Nathan R. Tucker, Timothy A. McKinsey, Marla R. Wolfson, Steven R. Houser
Publikováno v:
American journal of physiology. Heart and circulatory physiology. 323(4)
Approximately 50% of all heart failure (HF) diagnoses can be classified as HF with preserved ejection fraction (HFpEF). HFpEF is more prevalent in females compared with males, but the underlying mechanisms are unknown. We previously showed that press
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0533c0ec3093f75dbffdca87ff1e9495
https://pubmed.ncbi.nlm.nih.gov/36053749
https://pubmed.ncbi.nlm.nih.gov/36053749
Autor:
Deborah M Eaton, Remus M Berretta, Jacqueline E Lynch, Joshua G Travers, Kathleen C Woulfe, Ryan D Pfeiffer, Michelle L Hulke, Alexander R Hobby, Giana Schena, Jaslyn P Johnson, Markus Wallner, Nathan R Tucker, Timothy A McKinsey, Marla R Wolfson, Steven R Houser
Publikováno v:
Circulation. 144
Introduction: Approximately 50% of all heart failure (HF) diagnoses can be classified as HF with preserved ejection fraction (HFpEF), which has no FDA approved therapies. HFpEF is more prevalent in females compared to males, but the underlying mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2981644644f17732bcdc8bff808d5c4
https://doi.org/10.1161/circ.144.suppl_1.8955
https://doi.org/10.1161/circ.144.suppl_1.8955
Autor:
Timothy A. McKinsey, Jaslyn Johnson, Kathleen C. Woulfe, Giana Schena, Steven R. Houser, Jacqueline E Lynch, Joshua G Travers, Alexander R Hobby, Deborah M Eaton, M. Wallner, Marla R. Wolfson, Remus M. Berretta
Publikováno v:
Circulation Research. 129
Rationale: Heart Failure with preserved Ejection Fraction (HFpEF) accounts for approximately 50% of all HF diagnoses with no FDA approved therapies. HFpEF is more prevalent in females versus males, but the mechanisms driving the development of HFpEF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::303b5ed8eec01aa83fd7156b9c4644ce
https://doi.org/10.1161/res.129.suppl_1.p411
https://doi.org/10.1161/res.129.suppl_1.p411